Hooked on benzodiazepines: GABAA receptor subtypes and addiction

Trends in Neurosciences

Volumn 34, Issue 4, 2011, Pages 188-197

  Tan, Kelly R ^a   Rudolph, Uwe ^b   Lüscher, Christian ^a,c  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b MCLEAN HOSPITAL   (United States)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ALPHA1; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA3; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA5; 4 HYDROXYBUTYRIC ACID; 7 TERT BUTYL 3 (2,5 DIFLUOROPHENYL) 6 (2 METHYL 2H 1,2,4 TRIAZOL 3 YLMETHOXY) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; 8 AZIDO 5,6 DIHYDRO 5 METHYL 6 OXO 4H IMIDAZO[1,5 A][1,4]BENZODIAZEPINE 3 CARBOXYLIC ACID ETHYL ESTER; ALCOHOL; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; DIAZEPAM; DOPAMINE; FLUMAZENIL; FLUNITRAZEPAM; GLUTAMIC ACID; IMIDAZENIL; MIDAZOLAM; MUSCIMOL; OPIATE; TPA 023; UNCLASSIFIED DRUG; ZOLPIDEM; ZOLPIDEM TARTRATE; 4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; PROTEIN SUBUNIT;

ANTEROGRADE AMNESIA; ANXIETY DISORDER; BLADDER SPASM; CELL STRUCTURE; CONVULSION; DENDRITE; DISEASE ASSOCIATION; DRUG DEPENDENCE; DRUG INDICATION; DRUG TOLERANCE; HUMAN; INSOMNIA; MUSCLE SPASM; NERVE CELL PLASTICITY; NONHUMAN; NUCLEUS ACCUMBENS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; REVIEW; SLEEP DISORDER; VENTRAL TEGMENTUM; ADDICTION; ANIMAL; METABOLISM; NERVE CELL; REWARD;

ANIMALS; ANXIETY DISORDERS; BEHAVIOR, ADDICTIVE; BENZODIAZEPINES; DOPAMINE; GABA MODULATORS; HUMANS; NEURONS; PROTEIN SUBUNITS; RECEPTORS, GABA-A; REWARD; SUBSTANCE-RELATED DISORDERS; VENTRAL TEGMENTAL AREA;

EID: 79953164613     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2011.01.004     Document Type: Review

References (117)

1. Salzman C. Addiction to benzodiazepines. Psy. Quart. 1998, 69:251-261.
2. Schull P. Nursing Spectrum Drug Handbook 2009, McGraw Hill.
3. Sternbach L.H. The benzodiazepine story. J. Psychoact. Drugs 1983, 15:15-17.
4. Woods J.H., et al. Benzodiazepines: use, abuse, and consequences. Pharmacol. Rev. 1992, 44:151-347.
5. Schultz W., et al. A neural substrate of prediction and reward. Science 1997, 275:1593-1599.
6. Schultz W. Dopamine signals for reward value and risk: basic and recent data. Behav. Brain Funct. 2010, 6:24-32.
7. Zhang Y., et al. Effect of chronic 'binge cocaine' on basal levels and cocaine-induced increases of dopamine in the caudate putamen and nucleus accumbens of C57BL/6J and 129/J mice. Synapse 2003, 50:191-199.
8. Heikkinen A.E., et al. Long-lasting modulation of glutamatergic transmission in VTA dopamine neurons after a single dose of benzodiazepine agonists. Neuropsychopharmacology 2009, 34:290-298.
9. Tan K.R., et al. Neural bases for addictive properties of benzodiazepines. Nature 2010, 463:769-774.
10. Ungless M.A., et al. Single cocaine exposure in vivo induces long-term potentiation in dopamine neurons. Nature 2001, 411:583-587.
11. Nestler E.J. Is there a common molecular pathway for addiction?. Nat. Neurosci. 2005, 8:1445-1449.
12. Pierce R.C., Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?. Neurosci. Biobehav. Rev. 2006, 30:215-238.
13. Pinard A., et al. GABAB receptors: physiological functions and mechanisms of diversity. Adv. Pharmacol. 2010, 58:231-255.
14. Chebib M. GABAC receptor ion channels. Clin. Exp. Pharmacol. Physiol. 2004, 31:800-804.
15. Olsen R.W., Sieghart W. International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol. Rev. 2008, 60:243-260.
16. Barnard E.A., et al. International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharmacol. Rev. 1998, 50:291-313.
17. Moragues N., et al. cDNA cloning and expression of a gamma-aminobutyric acid A receptor epsilon-subunit in rat brain. Eur. J. Neurosci. 2000, 12:4318-4330.
18. Sieghart W., Sperk G. Subunit composition, distribution and function of GABA(A) receptor subtypes. Curr. Top. Med. Chem. 2002, 2:795.
19. Chang Y., et al. Stoichiometry of a recombinant GABAA receptor. J. Neurosci. 1996, 16:5415-5424.
20. Baumann S.W., et al. Forced subunit assembly in alpha1beta2gamma2 GABAA receptors. Insight into the absolute arrangement. J. Biol. Chem. 2002, 277:46020-46025.
21. Lüddens H., et al. Cerebellar GABAA receptor selective for a behavioural alcohol antagonist. Nature 1990, 346:648-651.
22. Kullmann D.M., et al. Presynaptic, extrasynaptic and axonal GABAA receptors in the CNS: where and why?. Prog. Biophys. Mol. Biol. 2005, 87:33-46.
23. Nusser Z., et al. Segregation of different GABAA receptors to synaptic and extrasynaptic membranes of cerebellar granule cells. J. Neurosci. 1998, 18:1693-1703.
24. Farrant M., Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat. Rev. Neurosci. 2005, 6:215-229.
25. Möhler H., Okada T. Benzodiazepine receptor: demonstration in the central nervous system. Science 1977, 198:849-851.
26. Tallman J.F., Hutchison A. Molecular biological insights into GABA and benzodiazepine receptor structure. Prog. Clin. Biol. Res. 1990, 361:231-255.
27. Sigel E., Buhr A. The benzodiazepine binding site of GABAA receptors. Trends Pharmacol. Sci. 1997, 18:425-429.
28. Sigel E. Mapping of the benzodiazepine recognition site on GABA(A) receptors. Cur. Top. Med. Chem. 2002, 2:833-839.
29. Wieland H.A., et al. A single histidine in GABAA receptors is essential for benzodiazepine agonist binding. J. Biol. Chem. 1992, 267:1426-1429.
30. Benson J.A., et al. Pharmacology of recombinant gamma-aminobutyric acidA receptors rendered diazepam-insensitive by point-mutated alpha-subunits. FEBS Lett. 1998, 431:400-404.
31. Korpi E.R., Seeburg P.H. Natural mutation of GABAA receptor alpha 6 subunit alters benzodiazepine affinity but not allosteric GABA effects. Eur. J. Pharmacol. 1993, 247:23-27.
32. Yang W., et al. Cloning and characterization of the human GABAA receptor alpha 4 subunit: identification of a unique diazepam-insensitive binding site. Eur. J. Pharmacol. 1995, 291:319-325.
33. Rudolph U., et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 1999, 401:796-800.
34. McKernan R.M., et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat. Neurosci. 2000, 3:587-592.
35. Löw K., et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 2000, 290:131-134.
36. Crestani F., et al. Trace fear conditioning involves hippocampal alpha5 GABA(A) receptors. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:8980-8985.
37. Dias R., et al. Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. J. Neurosci. 2005, 25:10682-10688.
38. Crestani F., et al. Molecular targets for the myorelaxant action of diazepam. Mol. Pharmacol. 2001, 59:442-445.
39. Collinson N., et al. Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor. J. Neurosci. 2002, 22:5572-5580.
40. Cheng V.Y., et al. Alpha5GABAA receptors mediate the amnestic but not sedative-hypnotic effects of the general anesthetic etomidate. J. Neurosci. 2006, 26:3713-3720.
41. Yamaguchi T., et al. Glutamatergic neurons are present in the rat ventral tegmental area. Eur. J. Neurosci. 2007, 25:106-118.
42. Dobi A., et al. Glutamatergic and nonglutamatergic neurons of the ventral tegmental area establish local synaptic contacts with dopaminergic and nondopaminergic neurons. J. Neurosci. 2010, 30:218-229.
43. Okada H., et al. Identification of GABAA receptor subunit variants in midbrain dopaminergic neurons. J. Neurochem. 2004, 89:7-14.
44. Gao B., et al. Neuron-specific expression of GABAA-receptor subtypes: differential association of the alpha 1- and alpha 3-subunits with serotonergic and GABAergic neurons. Neuroscience 1993, 54:881.
45. Gao B., Fritschy J.M. Selective allocation of GABAA receptors containing the alpha 1 subunit to neurochemically distinct subpopulations of rat hippocampal interneurons. Eur. J. Neurosci. 1994, 6:837-853.
46. Johnson S.W., North R.A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J. Neurosci. 1992, 12:483-488.
47. Cruz H.G., et al. Bi-directional effects of GABA(B) receptor agonists on the mesolimbic dopamine system. Nat. Neurosci. 2004, 7:153-159.
48. Labouèbe G., et al. RGS2 modulates coupling between GABAB receptors and GIRK channels in dopamine neurons of the ventral tegmental area. Nat. Neurosci. 2007, 10:1559-1568.
49. Lomazzi M., et al. Addictive drugs modulate GIRK-channel signaling by regulating RGS proteins. Trends Pharmacol. Sci. 2008, 29:544-549.
50. O'Brien D.P., White F.J. Inhibition of non-dopamine cells in the ventral tegmental area by benzodiazepines: relationship to A10 dopamine cell activity. Eur. J. Pharmacol. 1987, 142:343-354.
51. Finlay J.M., et al. Benzodiazepine-induced decreases in extracellular concentrations of dopamine in the nucleus accumbens after acute and repeated administration. Psychopharmacology 1992, 106:202-208.
52. Murai T., et al. Opposite effects of midazolam and beta-carboline-3-carboxylate ethyl ester on the release of dopamine from rat nucleus accumbens measured by in vivo microdialysis. Eur. J. Pharmacol. 1994, 261:65-71.
53. Pei Q., et al. Both systemic and local administration of benzodiazepine agonists inhibit the in vivo release of 5-HT from ventral hippocampus. Neuropharmacology 1989, 28:1061-1066.
54. Xi Z.X., Stein E.A. Nucleus accumbens dopamine release modulation by mesolimbic GABAA receptors-an in vivo electrochemical study. Brain Res. 1998, 798:156-165.
55. Andriamampandry C., et al. Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma-hydroxybutyrate (GHB). FASEB J. 2003, 17:1691-1693.
56. Kaupmann K., et al. Specific gamma-hydroxybutyrate-binding sites but loss of pharmacological effects of gamma-hydroxybutyrate in GABA(B)(1)-deficient mice. Eur. J. Neurosci. 2003, 18:2722-2730.
57. Doupnik C.A., et al. Measuring the modulatory effects of RGS proteins on GIRK channels. Meth. Enzymol. 2004, 389:131-154.
58. Saal D., et al. Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons. Neuron 2003, 37:577-582.
59. Brown M.T.C., et al. Drug-driven AMPA receptor redistribution mimicked by selective dopamine neuron stimulation. PLoS ONE 2010, 5:e15870.
60. Bellone C., Lüscher C. mGluRs induce a long-term depression in the ventral tegmental area that involves a switch of the subunit composition of AMPA receptors. Eur. J. Neurosci. 2005, 21:1280-1288.
61. Kauer J.A., Malenka R.C. Synaptic plasticity and addiction. Nat. Rev. Neurosci. 2007, 8:844-858.
62. Thomas M.J., et al. Neuroplasticity in the mesolimbic dopamine system and cocaine addiction. Br. J. Pharmacol. 2008, 154:327-342.
63. Lüscher C., Bellone C. Cocaine-evoked synaptic plasticity: a key to addiction?. Nat. Neurosci. 2008, 11:737-738.
64. Mameli M., et al. Cocaine-evoked synaptic plasticity: persistence in the VTA triggers adaptations in the NAc. Nat. Neurosci. 2009, 12:1036-1041.
65. Song J., et al. Benzodiazepine withdrawal-induced glutamatergic plasticity involves up-regulation of GluR1-containing alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors in hippocampal CA1 neurons. J. Pharmacol. Exp. Ther. 2007, 322:569-581.
66. Das P., et al. Increased AMPA receptor GluR1 subunit incorporation in rat hippocampal CA1 synapses during benzodiazepine withdrawal. J. Comp. Neurol. 2008, 511:832-846.
67. Rowlett J.K., et al. Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proc. Natl. Aca. Sci. U.S.A. 2005, 102:915-920.
68. Rowlett J.K., Lelas S. Comparison of zolpidem and midazolam self-administration under progressive-ratio schedules: consumer demand and labor supply analyses. Exp. Clin. Psychopharmacol. 2007, 15:328-337.
69. Atack J.R., et al. TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates. J. Pharmacol. Exp. Ther. 2006, 316:410-422.
70. Ator N.A., et al. Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2/3 subtypes. J. Pharmacol. Exp. Ther. 2010, 332:4-16.
71. Birdwood G., Craven M. Outmoded barbiturates. Br. Med. J. 1975, 1:148.
72. Isbell H., Fraser H.F. Addiction to analgesics and barbiturates. J. Pharmacol. Exp. Ther. 1950, 99:355-397.
73. Feng H.J., Macdonald R.L. Barbiturates require the N terminus and first transmembrane domain of the delta subunit for enhancement of alpha1beta3delta GABAA receptor currents. J. Biol. Chem. 2010, 285:23614-23621.
74. Wallner M., et al. Ethanol enhances alpha 4 beta 3 delta and alpha 6 beta 3 delta gamma-aminobutyric acid type A receptors at low concentrations known to affect humans. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:15218-15223.
75. Lovinger D.M., Homanics G.E. Tonic for what ails us?. high-affinity GABAA receptors and alcohol. Alcohol 2007, 41:139-143.
76. Brodie M.S., et al. Ethanol increases the firing rate of dopamine neurons of the rat ventral tegmental area in vitro. Brain Res. 1990, 508:65-69.
77. Brodie M.S., et al. Ethanol directly excites dopaminergic ventral tegmental area reward neurons. Alcoholism Clin. Exp. Res. 1999, 23:1848-1852.
78. Foddai M., et al. Acetaldehyde increases dopaminergic neuronal activity in the VTA. Neuropsychopharmacology 2004, 29:530-536.
79. h) is an ethanol target in midbrain dopamine neurons of mice. J. Neurophysiol. 2006, 95:619-626.
80. Gallegos R.A., et al. Adaptive responses of gamma-aminobutyric acid neurons in the ventral tegmental area to chronic ethanol. J. Pharmacol. Exp. Ther. 1999, 291:1045-1053.
81. Kalivas P.W., et al. Modulation of A10 dopamine neurons by gamma-aminobutyric acid agonists. J. Pharmacol. Exp. Ther. 1990, 253:858-866.
82. Grace A.A., Bunney B.S. Paradoxical GABA excitation of nigral dopaminergic cells: indirect mediation through reticulata inhibitory neurons. Eur. J. Pharmacol. 1979, 59:211-218.
83. Klitenick M.A., et al. Regulation of somatodendritic dopamine release in the ventral tegmental area by opioids and GABA: an in vivo microdialysis study. J. Neurosci. 1992, 12:2623-2632.
84. Aragona M. Abuse, dependence, and epileptic seizures after zolpidem withdrawal: review and case report. Clin. Neuropharmacol. 2000, 23:281-283.
85. Boulanger-Rostowsky L., et al. Dependence on zolpidem: a report of two cases. (In French.). L'Encéphale 2004, 30:153-155.
86. Svitek J., et al. Extensive craving in high dose zolpidem dependency. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:591-592.
87. Thompson D.M., et al. Imidazenil, a new anxiolytic and anticonvulsant drug, attenuates a benzodiazepine-induced cognition deficit in monkeys. J. Pharmacol. Exp. Ther. 1995, 273:1307-1312.
88. Auta J., et al. Imidazenil: a low efficacy agonist at alpha1- but high efficacy at alpha5-GABAA receptors fail to show anticonvulsant cross tolerance to diazepam or zolpidem. Neuropharmacology 2008, 55:148-153.
89. Auta J., et al. Anticonvulsant, anxiolytic, and non-sedating actions of imidazenil and other imidazo-benzodiazepine carboxamide derivatives. Pharmacol. Biochem. Behav. 2010, 95:383-389.
90. Anderson K.N., Shneerson J.M. Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam. J. Clin. Sleep Med. 2009, 5:235-239.
91. Hollister L.E., et al. Clinical uses of benzodiazepines. J. Clin. Psychopharmacol. 1993, 13:1S-169S.
92. McMullan J., et al. Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: a meta-analysis. J. Soc. Acad. Emerg. Med. 2010, 17:575-582.
93. Koht A., Moss J.I. Does midazolam cause retrograde amnesia, and can flumazenil reverse that amnesia?. Anesth. Analg. 1997, 85:211-212.
94. Pétursson H. The benzodiazepine withdrawal syndrome. Addiction 1994, 89:1455-1459.
95. Gabbard G.O. Gabbard's treatments of psychaitric disorders 2007, American Psychiatric Publishing.
96. Colvin R. Prescription Drug Addiction: The Hidden Epidemic. A Guide to Coping and Understanding 2008, Addicus Books, pp. 74-76.
97. Mameli M., et al. Rapid synthesis and synaptic insertion of GluR2 for mGluR-LTD in the ventral tegmental area. Science 2007, 317:530-533.
98. Borgland S.L., et al. Acute and chronic cocaine-induced potentiation of synaptic strength in the ventral tegmental area: electrophysiological and behavioral correlates in individual rats. J. Neurosci. 2004, 24:7482-7490.
99. Bellone C., Lüscher C. Cocaine triggered AMPA receptor redistribution is reversed in vivo by mGluR-dependent long-term depression. Nat. Neurosci. 2006, 9:636-641.
100. Nugent F.S., et al. Opioids block long-term potentiation of inhibitory synapses. Nature 2007, 446:1086-1090.
101. Nugent F.S., Kauer J.A. LTP of GABAergic synapses in the ventral tegmental area and beyond. J. Physiol. 2008, 586:1487-1493.
102. Liu Q., et al. Repeated cocaine exposure in vivo facilitates LTP induction in midbrain dopamine neurons. Nature 2005, 437:1027-1031.
103. Wolf M.E. The Bermuda Triangle of cocaine-induced neuroadaptations. Trends Neurosci. 2010, 33:391-398.
104. Robinson T.E., Kolb B. Structural plasticity associated with exposure to drugs of abuse. Neuropharmacology 2004, 47(Suppl. 1):33-46.
105. Belin D., et al. High impulsivity predicts the switch to compulsive cocaine-taking. Science 2008, 320:1352-1355.
106. Kalivas P.W., O'Brien C. Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology 2008, 33:166-180.
107. Eghbali M., et al. Hippocampal GABA(A) channel conductance increased by diazepam. Nature 1997, 388:71-75.
108. Rogers C.J., et al. Benzodiazepine and beta-carboline regulation of single GABAA receptor channels of mouse spinal neurones in culture. J. Physiol. 1994, 475:69-82.
109. Mellor J.R., Randall A.D. Frequency-dependent actions of benzodiazepines on GABAA receptors in cultured murine cerebellar granule cells. J. Physiol. 1997, 503:353-369.
110. Goldschen-Ohm M.P., et al. An epilepsy-related region in the GABA(A) receptor mediates long-distance effects on GABA and benzodiazepine binding sites. Mol. pharmacol. 2010, 77:35-45.
111. Campo-Soria C., et al. Mechanism of action of benzodiazepines on GABAA receptors. Br. J. Pharmacol. 2006, 148:984-990.
112. Rudolph U., Möhler H. GABA-based therapeutic approaches: GABAA receptor subtype functions. Curr. Opin. Pharmacol. 2006, 6:18-23.
113. Scott-Stevens P., et al. Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L-838417. Biopharm. Drug Dispos. 2005, 26:13-20.
114. Sieghart W. Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes. Pharmacol. Rev. 1995, 47:181-234.
115. Kucken A.M., et al. Structural requirements for imidazobenzodiazepine binding to GABAA receptors. Mol. Pharmacol. 2003, 63:289-296.
116. Buhr A., Sigel E. A point mutatin in the gamma2 subunit of gamma-aminobutyric acid type A receptors results in altered benzodiazepine binding site specificity. Proc. Natl. Aca. Sci. U.S.A. 1997, 94:8824-8829.
117. Giusti P., et al. Imidazenil: a new partial positive allosteric modulator of gamma aminobutyric acid (GABA) action at GABAA receptors. J. Pharmacol. Exp. Ther. 1993, 266:1018-1028.